# 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

> **NCT00826267** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 29 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** lapatinib
- **DRUG:** BIBW 2992
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00826267
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826267, "6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00826267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*